Genitourinary Medical Oncology Clinic
The UCSF Genitourinary Medical Oncology Clinic is home to some of the country's leading specialists in cancers of the genital and urinary systems. We provide the full spectrum of care, including screening exams, transrectal ultrasound and biopsy, diagnostic imaging, second opinions and treatments ranging from surgery to radiation therapy.
The clinic also offers education and support groups. In addition, patients may have access to the latest experimental therapies by participating in clinical trials.
Learn more about clinical trials and how they work.
Our locations
Our team
-
Rahul Aggarwal
MD
Genitourinary oncologist -
Hala Borno
MD
Medical oncologist -
Rohit Bose
MD, PhD
Genitourinary oncologist -
Jonathan Chou
MD, PhD
Genitourinary oncologist -
Ivan de Kouchkovsky
MD
Genitourinary oncologist -
Arpita Desai
MD
Genitourinary oncologist -
Kelly Fitzgerald
MD
Genitourinary oncologist -
Terence W. Friedlander
MD
Genitourinary oncologist -
Alexander R. Gottschalk
MD, PhD
Radiation oncologist -
I-Chow (Joe) Hsu
MD, FACR, FASTRO
Radiation oncologist -
Franklin Huang
MD, PhD
Medical oncologist -
Vadim S. Koshkin
MD
Genitourinary oncologist -
Daniel Kwon
MD
Genitourinary oncologist -
Elizabeth Pan
MD
Hematologist-oncologist -
Mack Roach III
MD
Radiation oncologist -
Eric J. Small
MD, FASCO
Genitourinary oncologist -
Anthony C. Wong
MD, PhD
Radiation oncologist -
Noah Younger
MD, PhD
Genitourinary oncologist -
Xiaolin Zhu
MD, PhD
Genitourinary oncologist -
Austin N. Angelidakis
NP, MSN
Nurse practitioner -
Iva Petrovchich Colón
NP, MSN
Nurse practitioner -
Dan Dee
RN
Nurse -
Stephanie Feng
FNP, MSN
Family nurse practitioner -
Ana Lichterman
NP, MSN
Nurse practitioner -
Sigrid Tarroza-David
RN
Nurse -
Allison Zaitchik
LCSW, MSW
Social worker
Clinical trials
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...
Recruiting
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV...
A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the National C...
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...
Recruiting
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...
On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Recruiting
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...
The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the...
Recruiting
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
The Decisional Conflict Scale measures personal perceptions of : a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in de...
Recruiting
Rankings & achievements
-
Among the top hospitals in the nation
-
Best in Northern California and No. 7 in the nation for cancer care
-
Best in Northern California for urology
-
Rated high-performing hospital for colon cancer surgery
-
in NIH funding for urology research
Accreditations & memberships
-
National Cancer Institute
The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
-
Commission on Cancer
UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
-
National Comprehensive Cancer Network
UCSF is a member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Support services
Plan your visit
What to Bring
- Recent radiology reports and images including X-ray, MRI and ultrasound films or CDs that relate to your condition
- Pathology reports of any biopsies or tests. Please bring glass pathology slides from the lab or office where the test was performed.
- Copies of all records relevant to your condition, including your last laboratory report and the most recent report or dictation from the doctor who referred you to UCSF. These items may include records from your primary care physician, oncologist or surgeon.
- Copies of your insurance cards
- A list of all your doctors, including their mailing addresses, telephone numbers and fax numbers
Related clinics
Our research initiatives
-
UCSF Helen Diller Family Comprehensive Cancer Center Research
UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.
